… who received erlotinib or gefitinib treatment and were followed up for more than 1 year were
included in this analysis. All patients took erlotinib or gefitinib at the discretion of the treating …

… Ongoing studies are testing the concurrent use of gefitinib or erlotinib and an mTOR inhibitor,
such as Everolimus (Novartis Pharmaceuticals USA, East Hanover, NJ), in patients with …

… -agent erlotinib observed in our trial are similar to first-line gefitinib among patients … erlotinib
did not result in better HRQL or symptom control than the other treatment arms in our study. …

… study retrospectively enrolled patients who had received gefitinib, erlotinib or afatinib for
first-line treatment of … Unlike previous studies that enrolled patients with Taiwan NHI-reimbursed …

… patients previously treated with gefitinib (n = 17) or erlotinib (n = … not received any therapy
with either gefitinib or erlotinib or with … informed consent and the studies were approved by the …

… The results shown in this study provide some insights on the mode of action and on the
potential clinical use of erlotinib versus gefitinib for the treatment of high-risk MDS and AML. One …

… treated with gefitinib or erlotinib according to their physician’s discretion and were included
in this study… had not received treatment with gefitinib or erlotinib at the time of data collection. …

… that was conducted to determine the efficacy and safety of sequential treatment … study,
our results suggest that intermittent combination treatment of chemotherapy and erlotinib/gefitinib …

… gefitinib versus carboplatin–paclitaxel in the IPASS study, which found that first-line EGFR
TKI therapy … The correlation of efficacy and rash in patients receiving erlotinib to treat a variety …

… detectable EGFR somatic mutation and who were treated with gefitinib or erlotinib. The aim
of the study was to correlate clinical response to gefitinib or erlotinib, time to progression, and …